BM 13505

Known as: BM 13.505, BM-13505 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1986-1997
01219861997

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1997
1997
The antithrombotic effect of desethyl KBT-3022, which is the main active metabolite of the new antiplatelet agent, KBT-3022… (More)
Is this relevant?
1995
1995
The effects of platelet-activating factor (PAF) on vascular resistance and capillary permeability were studied in the isolated… (More)
Is this relevant?
1993
1993
The antithrombotic effects of the thromboxane (TX) A2-receptor antagonist and aspirin were determined using a photochemically… (More)
Is this relevant?
1993
1993
The effects of KW-3635 (sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl) ethylidene]-6,11-dihydrodibenz-[b,e]oxepine-2… (More)
Is this relevant?
1992
1992
The purpose of the present experiments was to study the effects of endothelin-1 (ET-1) on vascular permeability and the… (More)
Is this relevant?
1992
1992
Thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors were characterized in rat vascular smooth muscle cells (VSMC). The specific… (More)
Is this relevant?
1989
1989
The ability of BM-13505, 4-[2-(4-chlorobenzenesulfonylamino) ethyl]-benzene acetic acid), a specific thromboxane/endoperoxide… (More)
Is this relevant?
1989
1989
1. Rat kidneys were perfused with Krebs-Henseleit solution and the perfusion pressure was monitored. After incubation with [3H… (More)
Is this relevant?
1988
1988
Splanchnic artery occlusion (SAO) followed by release of the occlusive clamps produces circulatory shock characterized by an… (More)
Is this relevant?
1986
1986
The new specific thromboxane receptor antagonist, BM-13505, was infused intravenously (1 mg/kg bolus and 1 mg/kg hr continuous… (More)
Is this relevant?